Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
Raket, Lars Lau LU ; Kühnel, Line ; Schmidt, Ellen ; Blennow, Kaj LU ; Zetterberg, Henrik LU and Mattsson-Carlgren, Niklas LU
(2020)
In Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
12(1).
- Abstract
Introduction: Several blood-based biomarkers are associated with neuronal injury, but their utility in interventional clinical trials is unclear. This study retrospectively evaluated the utility of plasma neurofilament light (NfL) and total tau (t-tau) in an 18-month trial in mild Alzheimer's disease (AD). Methods: Correlation and conditional independence analyses and Gaussian graphical models were used to investigate cross-sectional and longitudinal relations between NfL, t-tau, and clinical scales. Results: NfL had a stronger association than t-tau with clinical scales; t-tau did not hold additional information to that given by NfL (P > 0.05 at all time points). NfL held independent information about shorter-term (3- to 6-month)... (More)
Introduction: Several blood-based biomarkers are associated with neuronal injury, but their utility in interventional clinical trials is unclear. This study retrospectively evaluated the utility of plasma neurofilament light (NfL) and total tau (t-tau) in an 18-month trial in mild Alzheimer's disease (AD). Methods: Correlation and conditional independence analyses and Gaussian graphical models were used to investigate cross-sectional and longitudinal relations between NfL, t-tau, and clinical scales. Results: NfL had a stronger association than t-tau with clinical scales; t-tau did not hold additional information to that given by NfL (P > 0.05 at all time points). NfL held independent information about shorter-term (3- to 6-month) progression beyond patient age and clinical scores. However, no meaningful gain in power was found when adjusting a longitudinal analysis of cognitive scores for baseline NfL. Discussion: Plasma NfL is superior to t-tau in mild AD. The ability of NfL to detect changes before clinical manifestations makes it a promising biomarker of drug response in trials of disease-modifying drugs.
(Less)
- author
- Raket, Lars Lau
LU
; Kühnel, Line
; Schmidt, Ellen
; Blennow, Kaj
LU
; Zetterberg, Henrik
LU
and Mattsson-Carlgren, Niklas
LU
- organization
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, biomarkers, blood biomarkers, clinical trials, dementia, fluid biomarkers, neurofilament light, NfL, plasma biomarkers, t-tau, total tau
- in
- Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
- volume
- 12
- issue
- 1
- article number
- e12099
- publisher
- Elsevier
- external identifiers
-
- scopus:85100509312
- pmid:32995466
- ISSN
- 2352-8729
- DOI
- 10.1002/dad2.12099
- language
- English
- LU publication?
- yes
- id
- de06e0aa-61db-4e8f-bab3-d3ff3948972f
- date added to LUP
- 2021-02-19 09:01:53
- date last changed
- 2024-06-27 08:42:14
@article{de06e0aa-61db-4e8f-bab3-d3ff3948972f,
abstract = {{<p>Introduction: Several blood-based biomarkers are associated with neuronal injury, but their utility in interventional clinical trials is unclear. This study retrospectively evaluated the utility of plasma neurofilament light (NfL) and total tau (t-tau) in an 18-month trial in mild Alzheimer's disease (AD). Methods: Correlation and conditional independence analyses and Gaussian graphical models were used to investigate cross-sectional and longitudinal relations between NfL, t-tau, and clinical scales. Results: NfL had a stronger association than t-tau with clinical scales; t-tau did not hold additional information to that given by NfL (P > 0.05 at all time points). NfL held independent information about shorter-term (3- to 6-month) progression beyond patient age and clinical scores. However, no meaningful gain in power was found when adjusting a longitudinal analysis of cognitive scores for baseline NfL. Discussion: Plasma NfL is superior to t-tau in mild AD. The ability of NfL to detect changes before clinical manifestations makes it a promising biomarker of drug response in trials of disease-modifying drugs.</p>}},
author = {{Raket, Lars Lau and Kühnel, Line and Schmidt, Ellen and Blennow, Kaj and Zetterberg, Henrik and Mattsson-Carlgren, Niklas}},
issn = {{2352-8729}},
keywords = {{Alzheimer's disease; biomarkers; blood biomarkers; clinical trials; dementia; fluid biomarkers; neurofilament light; NfL; plasma biomarkers; t-tau; total tau}},
language = {{eng}},
number = {{1}},
publisher = {{Elsevier}},
series = {{Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring}},
title = {{Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease}},
url = {{http://dx.doi.org/10.1002/dad2.12099}},
doi = {{10.1002/dad2.12099}},
volume = {{12}},
year = {{2020}},
}